Science & Healthcare

Introduction: Chronic inflammatory bowel disease (HIBD), namely ulcerative colitis (UC) and Crohn's disease (CD) are among the most severe diseases of the digestive system.

Aim: to study the effeciency of infliximab biosimilar "Flammegis" in chronic inflammatory bowel disease.

Materials and methods. Biological therapy (BT) was carried out under the conditions of the gastroenterology department of the University Hospital of Semey State Medical University according to the developed and generally accepted methodology: the Flammegis intravenously infusion (Infliximab, manufacturer SELLTRION, Republic of Korea, Representative Office EKIS Pharmaceutical Plant CJSC since 2013), every 8 weeks with monitoring of the results of therapy at the beginning of treatment and after each session of the GIBT. The mean follow-up was 1 year 4 months.

Research results: In total, we carried out 41 sessions of the BT. The effectiveness of the GIBT was studied in 20 patients with HVSO: 90% with ulcerative colitis and 10% with Crohn's disease. When conducting a BT, after the first sessions, there was a reduction in stool frequency, a decrease in pathological impurities. After 3 sessions, persistent weight gain, increased hemoglobin levels, decreased leukocyte counts, and a significant decrease in ESR have been observed. The dynamics of fecal calprotectin in its final reflection is not presented, since the present study is still ongoing and there are no completed applications of BT yet.

Conclusions: After using Flammegis in HIBD patients after three months and six months, significant clinical effect was observed, confirmed by positive laboratory dynamics of signs of anemia and inflammatory activity of the disease, with a tendency to increase of this dynamics, as the programmatic application of BT continues, leading to ultimately, to induction of remission and improving the quality of life of patients with HIBD.